Everolimus
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-EVEROLIMUS |
|---|---|
| Type | Drug |
| Aliases | AfinitorVotubiaЕверолімус |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-BREAST DIS-PNET |
| Sources | SRC-BOLERO2-BASELGA-2012 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | mTOR inhibitor (rapalog) |
|---|---|
| Mechanism | Allosteric inhibitor of mTORC1 — blocks PI3K/AKT/mTOR pathway downstream of AKT. In HR+/HER2- breast: reverses endocrine resistance when added to AI (BOLERO-2 with exemestane) or fulvestrant (PrECOG/MANTA). Also approved in advanced RCC, pNET, and SEGA in tuberous sclerosis. |
| Typical dosing | 10 mg PO once daily continuous + exemestane 25 mg PO daily (BOLERO-2) OR + fulvestrant 500 mg IM standard schedule (PrECOG 0102). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Pivotal trial: BOLERO-2 (everolimus + exemestane). Off-label use with fulvestrant supported by PrECOG 0102 (Kornblum 2018) and clinical practice for fulvestrant-pretreated patients. Dexamethasone mouthwash 0.5 mg/5 mL swish/spit BID for first 8 weeks reduces G2+ stomatitis from ~33% to ~2% (SWISH trial).
Used By
Regimens
REG-EVEROLIMUS-EXEMESTANE- Everolimus + Exemestane (HR+/HER2- breast 3L+, post CDK4/6i and PI3Ki/AKTi)REG-EVEROLIMUS-MONO-PNET- Everolimus monotherapy (advanced/progressive pNET G1/G2; RADIANT-3)REG-FULVESTRANT-EVEROLIMUS-BREAST- Fulvestrant + everolimus (HR+/HER2- metastatic post-AI/CDK4/6i, no targetable mutation)